Connection
Michael Szarek to Subtilisins
This is a "connection" page, showing publications Michael Szarek has written about Subtilisins.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.054 |
|
|
|
-
Mohammadi KA, Brackin T, Schwartz GG, Steg PG, Szarek M, Manvelian G, Pordy R, Fazio S, Geba GP. Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials. Cancer Med. 2023 08; 12(16):16859-16868.
Score: 0.054